Kidney Cancer Drugs Market Is Anticipated To Show Growth By 2020
The global kidney cancer drugs market is expected to grow at a stable growth rate during the forecast period, due to various factors such as increasing geriatric population and rising incidence of kidney cancer as well as approval of novel drug molecules. However, few factors that are expected to negatively affect the growth of the market are increasing preference for generic drug variants and high prices of branded cancer drugs.
The global kidney cancer drugs market has been segmented based on major branded drugs and geography. Based on prominent brands of drugs, the kidney cancer drugs market is divided into: Afinitor (Everolimus), Avastin (Bevacizumab), Inlyta (Axitinib), Nexavar (Sorafenib), Proleukin (Aldesleukin/Interleukin-2), Sutent (Sunitinib), Torisel (Temsirolimus), and Votrient (Pazopanib). In terms of revenue, Sutent was the largest-selling kidney cancer drug in 2013. This is because Sutent is the most commonly prescribed drug in the first-line treatment against kidney cancer and is among the most studied drugs in its class for multiple indications, as it targets multiple receptor tyrosine kinases (RTKs).
In February 2006, the U.S. FDA approved Sunitinib for two indications, namely, RCC and gastrointestinal stromal tumor (GIST), making it the first cancer drug to receive approval in the U.S. However, GSK’s Votrient is expected become the market leader by 2017 surpassing Sutent and other competitors due to low pricing and superior first-line penetration, displaying the fastest growth rate at CAGR of over 40% from 2012 to 2016 and over 5% from 2016 to 2020. The market growth of Votrient is supported by the fact that during Phase III comparison trials, the drug showed better patient compatibility and safety profile with lower side effects as compared with interferon, placebo and other targeted therapies.
Request a Brochure of Kidney Cancer Drugs Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=537
North America is the largest market for kidney cancer drugs due the commercial availability of major branded drugs for kidney cancer treatment and presence of large patient pool suffering from various forms of kidney cancer. North America dominated the market mainly due to the presence of a large patient population and the lucrative health care system tailor-made for the pharmaceutical industry. Exclusive patent rights and presence of a large health care insurance base have driven the pharmaceutical market in the U.S., thereby making North America the market leader for kidney cancer drugs. Asia Pacific is expected to observe an admirable growth due to multiple factors such as rising incidence of renal cell carcinoma, growing geriatric population and rapid economic development in nations such as India, China, Singapore, Malaysia and others, that contribute to the growth of kidney cancer drugs market in the region.
At present, the market is highly consolidated and aggressive in nature due to the presence of biggest pharmaceutical giants such as Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG and Pfizer, Inc. Among these, Pfizer, Inc. grabbed the largest share of the global kidney cancer drugs market in 2013. Since, Sutent (Sunitinib) and Inlyta (Axitinib) are the leading drugs for the treatment of kidney cancer, the global market of kidney cancer drugs is ruled by one of the world’s largest biopharmaceutical companies, Pfizer, Inc. However, other established market players such as Novartis and GSK are focusing on expanding their geographical presence as well as distribution network in emerging nations, since Asia Pacific, Latin America and the Middle East are developing regions with an increasing incidence rate of various forms of kidney cancer and improving economic conditions.
Request a Sample of Kidney Cancer Drugs Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=537
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Kidney Cancer Drugs Market Is Anticipated To Show Growth By 2020 here
News-ID: 1846407 • Views: 166
More Releases from Transparency Market Research
Biomedical Refrigerators and Freezers Market Insights by 2027
According to a new market report published by Transparency Market Research titled “Biomedical Refrigerators and Freezers Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027,” the global biomedical refrigerator and freezer market is expected to reach a value of US$ 7122.4 Mn by 2027. In terms of value, the market is estimated to expand at a CAGR of 4.5% during the forecast period from 2019 to 2027.
Construction Market Trends and Research Insights by 2027
Transparency Market Research delivers key insights on the global construction market. In terms of revenue, the construction market is estimated to expand at a CAGR of ~4% during the forecast period, owing to numerous factors regarding which TMR offers thorough insights and forecasts in the construction market report. In the report, TMR predicts that the construction market would be largely driven by factors, such as rise in population and investments in
Microdisplay Market to rise at a CAGR of 22.3% by 2027 – TMR
According to a new research report on the global microdisplay market published by Transparency Market Research (TMR) the global microdisplay market is expected to reach value of US$ 5782.6 Mn by 2027, expanding at a CAGR of 22.3% from 2019 to 2027. According to the report, the global market is likely to continue to be influenced by a range of macroeconomic and market-specific factors in the next few years. In
Automotive Wiring Harness Market Research Insights by 2027
According to the report, the global automotive wiring harness market is projected to reach ~US$ 76 Bn by 2027, expanding at a CAGR of ~5% during the forecast period. Increasing GDP and technological advancements are major factors fueling the demand for automotive wiring harness market globally. The automotive wiring harness is undergoing an architectural revolution, owing to increase in incorporation of electronic components in vehicles, causing the weight of wiring
More Releases for Cancer
Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Cancer Molecular Biomarkers Market
Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients’ responses to treatments. On the basis of diagnostics, the cancer molecular
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and
Immune System Challenges Cancer
Cancer, as a word is in itself potent enough to send cold shivers down the spine of the readers. The trauma that the cancer patients go through in various treatments medical science has traditionally offered for this menace justifies the fear for it. Add to it the relatively low rates of survival and one would not be surprised to know that it is a leading cause of deaths. Scientific experiments